Epstein-Barr virus nuclear antigen 1 evades direct immune recognition by CD4+ T helper cells

European Journal of Immunology

Volumn 34, Issue 9, 2004, Pages 2500-2509

  Mautner, Josef ^a,b   Pich, Dagmar ^a   Nimmerjahn, Falk ^a   Milosevic, Slavoljub ^a   Adhikary, Dinesh ^a   Christoph, Heike ^a   Witter, Klaus ^c   Bornkamm, Georg W ^a   Hammerschmidt, Wolfgang ^a   Behrends, Uta ^a,b  

^a INSTITUTE OF EPIDEMIOLOGY   (Germany)

^b TECHNICAL UNIVERSITY OF MUNICH   (Germany)

^c UNIVERSITY OF MUNICH   (Germany)

Author keywords

Antigen presentation; Epstein Barr virus; MHC; T lymphocytes

Indexed keywords

ALANINE; CD4 ANTIGEN; EPITOPE; EPSTEIN BARR VIRUS ANTIGEN; GLYCINE; MAJOR HISTOCOMPATIBILITY ANTIGEN CLASS 2; EBV ENCODED NUCLEAR ANTIGEN 1; EBV-ENCODED NUCLEAR ANTIGEN 1;

ANIMAL CELL; ANTIGEN PURIFICATION; ANTIGEN RECOGNITION; ARTICLE; CELL CLONE; CELL IMMORTALIZATION; CONTROLLED STUDY; EPSTEIN BARR VIRUS; GENE OVEREXPRESSION; HELPER CELL; HUMAN; HUMAN CELL; IMMUNOTHERAPY; LYMPHOBLASTOID CELL LINE; MALIGNANT NEOPLASTIC DISEASE; NONHUMAN; PRIORITY JOURNAL; PROTEIN DOMAIN; STEADY STATE; TANDEM REPEAT; VIRUS STRAIN; ANTIGEN PRESENTATION; BURKITT LYMPHOMA; CELL LINE; IMMUNOLOGY;

ANTIGEN PRESENTATION; BURKITT LYMPHOMA; CELL LINE; EPSTEIN-BARR VIRUS NUCLEAR ANTIGENS; HERPESVIRUS 4, HUMAN; HUMANS; T-LYMPHOCYTES, HELPER-INDUCER;

EID: 4644221895     PISSN: 00142980     EISSN: None     Source Type: Journal    
DOI: 10.1002/eji.200324794     Document Type: Article

References (34)

1. Raab-Traub, N., Pathogenesis of Epstein-Barr virus and its associated malignancies. Semin. Virol. 1996. 7: 315-323.
2. Kieff, E., Epstein-Barr virus-increasing evidence of a link to carcinoma. N. Engl. J. Med. 1995. 333: 724-726.
3. Bornkamm, G. W. and Hammerschmidt, W., Molecular virology of Epstein-Barr virus. Philos. Trans. R. Soc. Lond. B Biol. Sci. 2001. 356: 437-459.
4. Gottschalk, S., Heslop, H. E. and Rooney, C. M., Treatment of Epstein-Barr virus-associated malignancies with specific T cells. Adv. Cancer Res. 2001. 84: 175-201.
5. Rickinson, A. B. and Moss, D. J., Human cytotoxic T lymphocyte responses to Epstein-Barr virus infection. Annu. Rev. Immunol. 1997. 15: 405-431.
6. Khanna, R. and Burrows, S. R., Role of cytotoxic T lymphocytes in Epstein-Barr virus-associated diseases. Annu. Rev. Microbiol. 2000. 54: 19-48.
7. Humme, S., Reisbach, G., Feederle, R., Delecluse, H. J., Bousset, K., Hammerschmidt, W. and Schepers, A., The EBV nuclear antigen 1 (EBNA1) enhances B cell immortalization several thousandfold. Proc. Natl. Acad. Sci. USA 2003. 100: 10989-10994.
8. Levitskaya, J., Coram, M., Levitsky, V., Imreh, S., Steigerwald-Mullen, P. M., Klein, G., Kurilla, M. G. and Masucci, M. G., Inhibition of antigen processing by the internal repeat region of the Epstein-Barr virus nuclear antigen-1. Nature 1995. 375: 685-688.
9. Levitskaya, J., Sharipo, A., Leonchiks, A., Ciechanover, A. and Masucci, M. G., Inhibition of ubiquitin/proteasome-dependent protein degradation by the Gly-Ala repeat domain of the Epstein-Barr virus nuclear antigen 1. Proc. Natl. Acad. Sci. USA 1997. 94: 12616-12621.
10. + T cell responses to EBV EBNA1: HLA class I presentation of the (Gly-Ala)-containing protein requires exogenous processing. Immunity 1997. 7: 791-802.
11. + T cell response: lessons from the EBV nuclear antigen EBNA1. J. Immunol. 2000. 165: 7078-7087.
12. Kalams, S. A. and Walker, B. D., The critical need for CD4 help in maintaining effective cytotoxic T lymphocyte responses. J. Exp. Med. 1998. 188: 2199-2204.
13. Hung, K., Hayashi, R., Lafond-Walker, A., Lowenstein, C., Pardoll, D. and Levitsky, H., The central role of CD4(+) T cells in the antitumor immune response. J. Exp. Med. 1998. 188: 2357-2368.
14. Abbas, A. K., Murphy, K. M. and Sher, A., Functional diversity of helper T lymphocytes. Nature 1996. 383: 787-793.
15. + T cell effectors inhibit Epstein-Barr virus-induced B cell proliferation. J. Virol. 2001. 75: 3740-3752.
16. Rooney, C. M., Smith, C. A., Ng, C. Y, Loftin, S., Li, C., Krance, R. A., Brenner, M. K. and Heslop, H. E., Use of gene-modified virus-specific T lymphocytes to control Epstein-Barr-virus-related lymphoproliferation. Lancet 1995. 345: 9-13.
17. Heslop, H. E. and Rooney, C. M., Adoptive cellular immunotherapy for EBV lymphoproliferative disease. Immunol. Rev. 1997. 157: 217-222.
18. Khanna, R., Burrows, S. R., Steigerwald-Mullen, P. M., Moss, D. J., Kurilla, M. G. and Cooper, L., Targeting Epstein-Barr virus nuclear antigen 1 (EBNA1) through the class II pathway restores immune recognition by EBNA1-specific cytotoxic T lymphocytes: evidence for HLA-DM-independent processing. Int. Immunol. 1997. 9: 1537-1543.
19. Munz, C., Bickham, K. L., Subklewe, M., Tsang, M. L., Chahroudi, A., Kurilla, M. G., Zhang, D., O'Donnell, M. and Steinman, R. M., Human CD4(+) T lymphocytes consistently respond to the latent Epstein-Barr virus nuclear antigen EBNA1. J. Exp. Med. 2000. 191: 1649-1660.
20. Leen, A., Meij, P., Redchenko, I., Middeldorp, J., Bloemena, E., Rickinson, A. and Blake, N., Differential immunogenicity of Epstein-Barr virus latent-cycle proteins for human CD4(+) T-helper 1 responses. J. Virol. 2001. 75: 8649-8659.
21. Paludan, C., Bickham, K., Nikiforow, S., Tsang, M. L., Goodman, K., Hanekom, W. A., Fonteneau, J. F., Stevanovic, S. and Munz, C., Epstein-Barr nuclear antigen 1-specific CD4(+) Th1 cells kill Burkitt's lymphoma cells. J. Immunol. 2002. 169: 1593-603.
22. Voo, K. S., Fu, T., Heslop, H. E., Brenner, M. K., Rooney, C. M. and Wang, R. F., Identification of HLA-DP3-restricted peptides from EBNA1 recognized by CD4(+) T cells. Cancer Res. 2002. 62: 7195-7199.
23. Kruger, S., Schroers, R., Rooney, C. M., Gahn, B. and Chen, S. Y., Identification of a naturally processed HLA-DR-restricted T-helper epitope in Epstein-Barr virus nuclear antigen type 1. J. Immunother. 2003. 26: 212-221.
24. Delecluse, H. J., Hilsendegen, T., Pich, D., Zeidler, R. and Hammerschmidt, W., Propagation and recovery of intact, infectious Epstein-Barr virus from prokaryotic to human cells. Proc. Natl. Acad. Sci. USA 1998. 95: 8245-8250.
25. Sanderson, S., Frauwirth, K. and Shastri, N., Expression of endogenous peptide-major histocompatibility complex class II complexes derived from invariant chain-antigen fusion proteins. Proc. Natl. Acad. Sci. USA 1995. 92: 7217-7221.
26. Gires, O., Zimber-Strobl, U., Gonnella, R., Ueffing, M., Marschall, G., Zeidler, R., Pich, D. and Hammerschmidt, W., Latent membrane protein 1 of Epstein-Barr virus mimics a constitutively active receptor molecule. EMBO J. 1997. 16: 6131-6140.
27. Sternas, L., Middleton, T. and Sugden, B., The average number of molecules of Epstein-Barr nuclear antigen 1 per cell does not correlate with the average number of Epstein-Barr virus (EBV) DNA molecules per cell among different clones of EBV-immortalized cells. J. Virol. 1990. 64: 2407-2410.
28. Khanna, R., Moss, D. J. and Burrows, S. R., Vaccine strategies against Epstein-Barr virus-associated diseases: lessons from studies on cytotoxic T cell-mediated immune regulation. Immunol. Rev. 1999. 170: 49-64.
29. Nimmerjahn, F., Milosevic, S., Behrends, U., Jaffee, E. M., Pardoll, D. M., Bornkamm, G. W. and Mautner, J., Major histocompatibility complex class II-restricted presentation of a cytosolic antigen by autophagy. Eur. J. Immunol. 2003. 33: 1250-1259.
30. Kilger, E. and Hammerschmidt, W., Genetic analysis and gene expression with mini-Epstein-Barr virus plasmids. Methods Mol. Biol. 2001. 174: 23-35.
31. O'Connor, M., Peifer, M. and Bender, W., Construction of large DNA segments in Escherichia coli. Science 1989. 244: 1307-1312.
32. Delecluse, H. J., Pich, D., Hilsendegen, T., Baum, C. and Hammerschmidt, W., A first-generation packaging cell line for Epstein-Barr virus-derived vectors. Proc. Natl. Acad. Sci. USA 1999. 96: 5188-5193.
33. Neuhierl, B., Feederle, R., Hammerschmidt, W. and Delecluse, H. J., Glycoprotein gp110 of Epstein-Barr virus determines viral tropism and efficiency of infection. Proc. Natl. Acad. Sci. USA 2002. 99: 15036-15041.
34. + T cells by recombinant influenza viruses. Eur. J. Immunol. 2003. 33: 3331-3341.